SG11202104609SA - Macrocyclic tyrosine kinase inhibitor and uses thereof - Google Patents

Macrocyclic tyrosine kinase inhibitor and uses thereof

Info

Publication number
SG11202104609SA
SG11202104609SA SG11202104609SA SG11202104609SA SG11202104609SA SG 11202104609S A SG11202104609S A SG 11202104609SA SG 11202104609S A SG11202104609S A SG 11202104609SA SG 11202104609S A SG11202104609S A SG 11202104609SA SG 11202104609S A SG11202104609S A SG 11202104609SA
Authority
SG
Singapore
Prior art keywords
tyrosine kinase
kinase inhibitor
macrocyclic
macrocyclic tyrosine
inhibitor
Prior art date
Application number
SG11202104609SA
Inventor
Bin Liu
Original Assignee
Shandong Xuanzhu Pharma Co Ltd
Xuanzhu Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Xuanzhu Pharma Co Ltd, Xuanzhu Biopharmaceutical Co Ltd filed Critical Shandong Xuanzhu Pharma Co Ltd
Publication of SG11202104609SA publication Critical patent/SG11202104609SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
SG11202104609SA 2018-11-09 2019-11-08 Macrocyclic tyrosine kinase inhibitor and uses thereof SG11202104609SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811328658 2018-11-09
CN201910091922 2019-01-30
PCT/CN2019/116459 WO2020094112A1 (en) 2018-11-09 2019-11-08 Macrocyclic tyrosine kinase inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
SG11202104609SA true SG11202104609SA (en) 2021-06-29

Family

ID=70611691

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104609SA SG11202104609SA (en) 2018-11-09 2019-11-08 Macrocyclic tyrosine kinase inhibitor and uses thereof

Country Status (9)

Country Link
US (1) US20210401814A1 (en)
EP (1) EP3878854A4 (en)
JP (1) JP7190036B2 (en)
KR (1) KR20210088675A (en)
CN (1) CN113166155A (en)
AU (1) AU2019375825B2 (en)
PH (1) PH12021551057A1 (en)
SG (1) SG11202104609SA (en)
WO (1) WO2020094112A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113135938B (en) * 2020-01-19 2022-06-14 山东轩竹医药科技有限公司 Substituted macrocyclic tyrosine kinase inhibitors and uses thereof
JP2023525997A (en) * 2020-05-08 2023-06-20 シャンドン シュエンヂュ ファーマ カンパニー リミテッド Crystal forms of macrocycle tyrosine kinase inhibitors and methods for their preparation
CN111875620B (en) * 2020-09-28 2020-12-11 上海美迪西生物医药股份有限公司 Pyrazolopyrimidine macrocyclic derivative and application thereof
CN117597128A (en) * 2021-08-23 2024-02-23 正大天晴药业集团股份有限公司 Use of amino-containing macrocyclic compounds for the treatment of TRK kinase mediated tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028116A1 (en) 2008-09-08 2010-03-11 Merck Serono S.A. Macrocyclics pyrimidines as aurora kinase inhibitors
BR122019024201B1 (en) 2010-05-20 2021-08-03 Array Biopharma Inc MACROCYCLIC COMPOUND AS TRK KINASE INHIBITORS, ITS USE, AND PHARMACEUTICAL COMPOSITION
BR112013029711B1 (en) * 2011-05-19 2020-05-12 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii COMPOUNDS
MY193524A (en) * 2014-01-24 2022-10-18 Turning Point Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
JOP20190092A1 (en) * 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
EP3706749B1 (en) 2017-11-10 2024-03-13 Angex Pharmaceutical, Inc. Macrocyclic compounds as trk kinase inhibitors and uses thereof

Also Published As

Publication number Publication date
EP3878854A4 (en) 2022-08-10
US20210401814A1 (en) 2021-12-30
AU2019375825A8 (en) 2021-07-15
AU2019375825A1 (en) 2021-06-24
JP2022506802A (en) 2022-01-17
JP7190036B2 (en) 2022-12-14
EP3878854A1 (en) 2021-09-15
KR20210088675A (en) 2021-07-14
WO2020094112A1 (en) 2020-05-14
CN113166155A (en) 2021-07-23
AU2019375825B2 (en) 2022-09-15
PH12021551057A1 (en) 2021-12-06

Similar Documents

Publication Publication Date Title
IL282487A (en) Tyk2 inhibitors and uses thereof
EP3868762A4 (en) Mst1 kinase inhibitor and use thereof
IL271999A (en) Tyk2 inhibitors and uses thereof
EP3293177A4 (en) Tyrosine kinase inhibitor and pharmaceutical composition comprising same
EP3177366A4 (en) Bruton's tyrosine kinase inhibitor combinations and uses thereof
SG11202104609SA (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
EP3728270A4 (en) Macrocyclic kinase inhibitors and their use
IL282090A (en) Tyk2 inhibitors and uses thereof
SG10201913927VA (en) Kinase inhibitors and uses thereof
EP3572400C0 (en) Ezh2 inhibitor and use thereof
EP3783000A4 (en) Macrocyclic kinase inhibitor
ZA202002172B (en) Pde9 inhibitor and use thereof
IL283409A (en) Tyk2 inhibitors and uses thereof
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
EP3511327A4 (en) Tyrosine kinase inhibitor and application thereof
IL277600A (en) Axl kinase inhibitors and use of the same
EP3543239A4 (en) Selective bruton's tyrosine kinase inhibitor and use thereof
EP3810132A4 (en) Taire family kinase inhibitors and uses thereof
IL283599A (en) Tyrosine kinase inhibitors, compositions and methods there of
PL3689351T3 (en) Quinoline derivative and application thereof as tyrosine kinase inhibitor
IL282588A (en) Heterocyclic kinase inhibitors and uses thereof
EP3328380A4 (en) Bruton's tyrosine kinase inhibitor combinations and uses thereof
IL278973A (en) Novel benzodiazepine derivatives and uses thereof
EP3564242A4 (en) Compound for selectively inhibiting kinase and use thereof
EP3572415A4 (en) Jak kinase inhibitor and preparation method and use thereof